J G Coen van Hasselt
Overview
Explore the profile of J G Coen van Hasselt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Otto M, van der Heijden K, Schoones J, van Esdonk M, Borghans L, Jacobs G, et al.
Clin Pharmacokinet
. 2025 Feb;
PMID: 39982684
No abstract available.
2.
Straub V, Barti B, Tandar S, Stevens A, van Egmond N, van der Wel T, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(8):e2421717122.
PMID: 39977325
While it is known that endocannabinoids (eCB) modulate multiple neuronal functions, the molecular mechanism governing their release and transport remains elusive. Here, we propose an "" model, wherein the formation...
3.
Gulave B, van den Maagdenberg H, van Boven L, van Westen G, de Lange E, van Hasselt J
Pharm Res
. 2025 Feb;
42(2):281-289.
PMID: 39930309
Introduction: The unbound brain-to-plasma partition coefficient (K) is an essential parameter for predicting central nervous system (CNS) drug disposition using physiologically-based pharmacokinetic (PBPK) modeling. K values for specific compounds are...
4.
Otto M, van der Heijden K, Schoones J, van Esdonk M, Borghans L, Jacobs G, et al.
Clin Pharmacokinet
. 2025 Jan;
64(1):53-66.
PMID: 39812743
Background And Objective: Psilocybin is currently being extensively studied as a potential therapeutic agent for multiple psychiatric disorders. Here, a systematic literature review of all published pharmacokinetic data on the...
5.
Gulave B, Lesmana A, de Lange E, van Hasselt J
J Pharmacokinet Pharmacodyn
. 2025 Jan;
52(1):11.
PMID: 39776000
P-glycoprotein (P-gp) is a key efflux transporter and may be involved in drug-drug interactions (DDIs) at the blood-brain barrier (BBB), which could lead to changes in central nervous system (CNS)...
6.
Kok M, Hankemeier T, van Hasselt J
Microbiol Spectr
. 2024 Dec;
13(1):e0140924.
PMID: 39656019
The infectious microenvironment in chronic respiratory tract infections is characterized by substantial variability in nutrient conditions, which may impact colonization and treatment response of pathogens. Metabolic adaptation of the cystic...
7.
van den Maagdenberg H, Sicho M, Araripe D, Luukkonen S, Schoenmaker L, Jespers M, et al.
J Cheminform
. 2024 Nov;
16(1):128.
PMID: 39543652
Building reliable and robust quantitative structure-property relationship (QSPR) models is a challenging task. First, the experimental data needs to be obtained, analyzed and curated. Second, the number of available methods...
8.
de Jong L, van de Kreeke M, Ahmadi M, Swen J, Knibbe C, van Hasselt J, et al.
Clin Pharmacokinet
. 2024 Oct;
63(11):1585-1595.
PMID: 39463211
Background And Objective: CYP450 (CYP) phenotyping involves quantifying an individual's plasma clearance of CYP-specific probe drugs, as a proxy for in vivo CYP enzyme activity. It is increasingly applied to...
9.
Sanz-Codina M, van Os W, Pham A, Jorda A, Wolf-Duchek M, Bergmann F, et al.
J Antimicrob Chemother
. 2024 Oct;
79(12):3281-3288.
PMID: 39373642
Background: Cefiderocol may potentially be used to treat skin and soft tissue infections (SSTIs). However, the pharmacokinetics of cefiderocol in human soft tissues have not yet been determined. The objective...
10.
van Groesen E, Mons E, Kotsogianni I, Arts M, Tehrani K, Wade N, et al.
Sci Transl Med
. 2024 Aug;
16(759):eabo4736.
PMID: 39110780
Gram-positive bacterial infections present a major clinical challenge, with methicillin- and vancomycin-resistant strains continuing to be a cause for concern. In recent years, semisynthetic vancomycin derivatives have been developed to...